[go: up one dir, main page]

PE20180315A1 - Anticuerpos para cd40 - Google Patents

Anticuerpos para cd40

Info

Publication number
PE20180315A1
PE20180315A1 PE2017002834A PE2017002834A PE20180315A1 PE 20180315 A1 PE20180315 A1 PE 20180315A1 PE 2017002834 A PE2017002834 A PE 2017002834A PE 2017002834 A PE2017002834 A PE 2017002834A PE 20180315 A1 PE20180315 A1 PE 20180315A1
Authority
PE
Peru
Prior art keywords
antibodies
fcyriib
antigen
bind
administering
Prior art date
Application number
PE2017002834A
Other languages
English (en)
Inventor
Bryan C Barnhart
Aaron P Yamniuk
Brigitte Devaux
Shannon L Okada
Brenda L Stevens
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20180315A1 publication Critical patent/PE20180315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere anticuerpos agonistas, o porciones de union al antigeno del mismo que se unen a CD40 humano. Tales anticuerpos comprenden opcionalmente regiones Fc con especificidad mejorada para FcyRIIb. La invencion tambien proporciona metodos para el tratamiento de cancer o infeccion cronica administrando los anticuerpos de la invencion a un sujeto en necesidad del mismo.
PE2017002834A 2015-06-29 2016-06-28 Anticuerpos para cd40 PE20180315A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186076P 2015-06-29 2015-06-29
US201562252615P 2015-11-09 2015-11-09

Publications (1)

Publication Number Publication Date
PE20180315A1 true PE20180315A1 (es) 2018-02-09

Family

ID=56322325

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002834A PE20180315A1 (es) 2015-06-29 2016-06-28 Anticuerpos para cd40

Country Status (18)

Country Link
US (4) US20180142030A1 (es)
EP (1) EP3313880B1 (es)
JP (2) JP7350467B2 (es)
KR (1) KR102671348B1 (es)
CN (2) CN115838427A (es)
AU (2) AU2016285913B2 (es)
BR (1) BR112017027549A2 (es)
CA (1) CA2990012A1 (es)
CL (2) CL2017003427A1 (es)
CO (1) CO2018000809A2 (es)
EA (1) EA035268B1 (es)
ES (1) ES3039629T3 (es)
HK (1) HK1252666A1 (es)
IL (1) IL256499B (es)
MX (2) MX395257B (es)
PE (1) PE20180315A1 (es)
WO (1) WO2017004006A1 (es)
ZA (1) ZA201708704B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3556774T3 (pl) 2011-03-11 2024-07-01 Beth Israel Deaconess Medical Center Inc. Przeciwciała anty-cd40 i ich zastosowania
MA47472A (fr) 2014-08-12 2019-12-18 Alligator Bioscience Ab Anticorps
UY36757A (es) * 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
IL261602B2 (en) 2016-03-04 2024-06-01 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
DK3468997T5 (da) 2016-06-08 2024-09-09 Xencor Inc Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
AR111830A1 (es) 2017-05-25 2019-08-21 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
KR20200012920A (ko) 2017-06-01 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-cd40 항체, 이의 항원 결합 단편 및 이의 의학적 용도
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
CN112020517B (zh) * 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
JP7212138B2 (ja) * 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
CA3107660A1 (en) * 2018-07-26 2020-01-30 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20220025060A1 (en) * 2018-11-30 2022-01-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereof
TW202021620A (zh) 2018-11-30 2020-06-16 大陸商江蘇恒瑞醫藥股份有限公司 一種cd40抗體藥物組合物及其用途
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
WO2020207470A1 (zh) 2019-04-10 2020-10-15 南开大学 抗cd40抗体及其用途
JP2023516459A (ja) 2020-03-09 2023-04-19 ブリストル－マイヤーズ スクイブ カンパニー 増強されたアゴニスト活性を有するｃｄ４０に対する抗体
AU2021268885B2 (en) * 2020-05-06 2025-02-20 Navicure Biopharmaceuticals Limited Fusion proteins for immunotherapy against cancer and infectious diseases
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
US20240336693A1 (en) * 2021-08-10 2024-10-10 Apexigen, Inc. Biomarkers for cd40 agonist therapy
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2012087928A2 (en) * 2010-12-20 2012-06-28 The Rockefeller University Modulating agonistic tnfr antibodies
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
BR112016007112A2 (pt) 2013-12-20 2017-09-19 Hoffmann La Roche Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
JP6682498B2 (ja) 2014-03-24 2020-04-15 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
IL261602B2 (en) * 2016-03-04 2024-06-01 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity

Also Published As

Publication number Publication date
CN115838427A (zh) 2023-03-24
CL2022001189A1 (es) 2023-01-20
CO2018000809A2 (es) 2018-04-19
ES3039629T3 (en) 2025-10-23
KR102671348B1 (ko) 2024-05-30
MX395257B (es) 2025-03-25
US20210054091A1 (en) 2021-02-25
IL256499B (en) 2021-12-01
CN107771184A (zh) 2018-03-06
CN107771184B (zh) 2022-11-01
US20180142030A1 (en) 2018-05-24
KR20180021834A (ko) 2018-03-05
JP2022028666A (ja) 2022-02-16
US10844130B2 (en) 2020-11-24
JP7350467B2 (ja) 2023-09-26
EP3313880A1 (en) 2018-05-02
CA2990012A1 (en) 2017-01-05
US20190248911A1 (en) 2019-08-15
EP3313880B1 (en) 2025-08-06
EA201890175A1 (ru) 2018-06-29
US20240336695A1 (en) 2024-10-10
AU2022228155A1 (en) 2022-11-10
AU2016285913B2 (en) 2022-06-16
HK1252666A1 (zh) 2019-05-31
BR112017027549A2 (pt) 2018-09-11
IL256499A (en) 2018-02-28
ZA201708704B (en) 2019-08-28
WO2017004006A1 (en) 2017-01-05
JP2018526978A (ja) 2018-09-20
AU2016285913A1 (en) 2018-02-15
CL2017003427A1 (es) 2018-05-04
MX2017016253A (es) 2018-04-20
EA035268B1 (ru) 2020-05-22
MX2022002504A (es) 2022-04-06

Similar Documents

Publication Publication Date Title
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
MX2015012644A (es) Tratamiento de cataplejia.
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
ECSP17008984A (es) Tratamientos conjuntos con anticuerpos anti cd40
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
EA201691541A1 (ru) Новые анти-baff антитела
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
EA201590412A1 (ru) Композиции антител и их применения
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX391141B (es) Anticuerpos anti-ceramida.
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
EA201791970A1 (ru) Способ лечения первичного склерозирующего холангита
CO2018001238A2 (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
BR112017025264A2 (pt) tratamento de prurido
MX386543B (es) Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
EA201891445A1 (ru) Молекулы антител, которые связываются с tnf-альфа
AR105171A1 (es) Anticuerpos contra cd40 con actividad agonista mejorada